Homburger advises PHOENIX Pharma Switzerland on its joint venture with Voigt Group

On October 18, 2022, PHOENIX Pharma Switzerland, a subsidiary of the family-owned PHOENIX group, and Voigt Holding announced that they agreed to establish a 50/50-joint venture to combine their pharmaceutical distribution services and pre-wholesale activities. The closing of the joint venture is subject to the approval by the Swiss Competition Commission.

Homburger advises PHOENIX Pharma Switzerland on the transaction. The Homburger team is led by partner Frank Gerhard (Corporate / M&A) and comprises counsel Andreas Burger (Competition, Regulatory) as well as associates Marc Schamaun, Patrick Schmidt (both Corporate / M&A), Allegra Arnold, Daniel Lütolf (both Competition, Regulatory), Angela Casey, Nicole Hilpert (both Employment and Executive Compensation), and junior associate Nicolas Wetzel (Corporate / M&A).